BACKGROUND: In-stent restenosis is caused by neointimal hyperplasia. Sirolimus (rapamycin; Wyeth Research, Radnor, Pennsylvania, USA) inhibits vascular smooth muscle cell proliferation and we evaluated the efficacy of sirolimus in reducing neointimal formation in a rabbit iliac model and in-vivo pharmacokinetics in the porcine coronary model. DESIGN: Randomized, blinded, prospective animal study. METHODS: Bilateral rabbit iliac artery stent implantation was performed using crossflex stents (Cordis Corporation, Warren, New Jersey, USA) coated with sirolimus incorporated in a nonerodable polymer. Arteries were randomized to one of four stent groups: uncoated stents (n = 8); polymer control stents (n = 10); low-dose sirolimus-eluting stents (n = 9); and high-dose sirolimus-eluting stents (n = 10). Histomorphometry was performed at 28 days. Arterial tissue and stents were retrieved at 8, 14 and 28 days and blood samples were obtained daily during the first week. RESULTS: Treatment with low-dose sirolimus was associated with a 23% (P = NS) reduction in neointimal area and treatment with high-dose sirolimus with a 45% (P < 0.05) reduction. Sustained drug release from the stent and prolonged intramural arterial deposition were confirmed for up to 28 days. No detectable sirolimus was found in the blood after 2 days. CONCLUSION: Controlled-release local delivery of a cell-cycle inhibitor from a nonerodable polymer-coated stent reduced neointimal formation in rabbit iliac arteries in a dose-dependent manner and represents a promising strategy for preventing restenosis.
BACKGROUND: In-stent restenosis is caused by neointimal hyperplasia. Sirolimus (rapamycin; Wyeth Research, Radnor, Pennsylvania, USA) inhibits vascular smooth muscle cell proliferation and we evaluated the efficacy of sirolimus in reducing neointimal formation in a rabbit iliac model and in-vivo pharmacokinetics in the porcine coronary model. DESIGN: Randomized, blinded, prospective animal study. METHODS: Bilateral rabbit iliac artery stent implantation was performed using crossflex stents (Cordis Corporation, Warren, New Jersey, USA) coated with sirolimus incorporated in a nonerodable polymer. Arteries were randomized to one of four stent groups: uncoated stents (n = 8); polymer control stents (n = 10); low-dose sirolimus-eluting stents (n = 9); and high-dose sirolimus-eluting stents (n = 10). Histomorphometry was performed at 28 days. Arterial tissue and stents were retrieved at 8, 14 and 28 days and blood samples were obtained daily during the first week. RESULTS: Treatment with low-dose sirolimus was associated with a 23% (P = NS) reduction in neointimal area and treatment with high-dose sirolimus with a 45% (P < 0.05) reduction. Sustained drug release from the stent and prolonged intramural arterial deposition were confirmed for up to 28 days. No detectable sirolimus was found in the blood after 2 days. CONCLUSION: Controlled-release local delivery of a cell-cycle inhibitor from a nonerodable polymer-coated stent reduced neointimal formation in rabbit iliac arteries in a dose-dependent manner and represents a promising strategy for preventing restenosis.
Authors: Ashok S Thakkar; Atul D Abhyankar; Sameer I Dani; Darshan N Banker; Parvinder I Singh; Sanjay A Parmar; Anita A Mehta Journal: Indian Heart J Date: 2012 May-Jun
Authors: Salvatore Brugaletta; Hector M Garcia-Garcia; Scot Garg; Josep Gomez-Lara; Roberto Diletti; Yoshinobu Onuma; Robert Jan van Geuns; Dougal McClean; Dariusz Dudek; Leif Thuesen; Bernard Chevalier; Stephan Windecker; Robert Whitbourn; Cecile Dorange; Karine Miquel-Hebert; Krishnankutty Sudhir; John A Ormiston; Patrick W Serruys Journal: Int J Cardiovasc Imaging Date: 2010-10-13 Impact factor: 2.357
Authors: Yann Gouëffic; Susan Potter-Perigo; Christina K Chan; Pamela Y Johnson; Kathleen Braun; Steven P Evanko; Thomas N Wight Journal: Atherosclerosis Date: 2006-12-14 Impact factor: 5.162
Authors: Alexander Sedaghat; Jan-Malte Sinning; Kathrin Paul; Gregor Kirfel; Georg Nickenig; Nikos Werner Journal: Clin Res Cardiol Date: 2013-02-10 Impact factor: 5.460
Authors: Taichi Sakaguchi; Shi Fang Yan; Shi Du Yan; Dmitri Belov; Ling Ling Rong; Monica Sousa; Martin Andrassy; Steven P Marso; Stephan Duda; Bernd Arnold; Birgit Liliensiek; Peter P Nawroth; David M Stern; Ann Marie Schmidt; Yoshifumi Naka Journal: J Clin Invest Date: 2003-04 Impact factor: 14.808
Authors: Joseph P Kilroy; Ali H Dhanaliwala; Alexander L Klibanov; Douglas K Bowles; Brian R Wamhoff; John A Hossack Journal: Ann Biomed Eng Date: 2015-04-17 Impact factor: 3.934